Collecting and Protecting Patient Data

Date June 13, 2017

The goal of any clinical trial or post marketing surveillance effort (Phase IV studies) is to collect patient level data to evaluate a drug’s effectiveness while protecting the identity of the patient from those researcher evaluating the results of the trail.

The challenge in this age of readily accessible personal data is to identify ways to further protect a person’s identity for traditional clinical trials while preparing to leverage new technologies like IoMT and data collection apps to pro-actively collect Phase IV clinical data.

ADLT™ provides the solution to this challenge. By assigning patients a digital key that masks their identity: